A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (XanaMIA-DR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04983368|
Recruitment Status : Completed
First Posted : July 30, 2021
Last Update Posted : April 8, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's disease.
The purpose of this study in older volunteers is to investigate the smallest dose of Xanamem® (5 mg or 10 mg) which works and to investigate which dose in this study will be used in the upcoming clinical trials in patients.
|Condition or disease||Intervention/treatment||Phase|
|Mild Cognitive Impairment Alzheimer's Disease||Drug: Xanamem® 5 mg Drug: Placebo Drug: Xanamem® 10 mg||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||107 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Volunteer subjects will be randomly assigned to 1 of 3 treatment groups to receive either 5 mg Xanamem®, 10 mg Xanamem® or placebo in the ratio of 1:1:1 with approximately 35 subjects in each treatment group. This sample size has been selected to allow for approximately 30 subjects per treatment group to complete the study.|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Masking Description:||Study treatment is blinded for participants, investigators.|
|Official Title:||XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem® in Healthy Elderly Volunteers|
|Actual Study Start Date :||June 30, 2021|
|Actual Primary Completion Date :||February 11, 2022|
|Actual Study Completion Date :||February 11, 2022|
Experimental: Xanamem® 5 mg
Oral Xanamem® capsules 5 mg, to be administered once daily
Drug: Xanamem® 5 mg
Oral Xanamem® ("UE2343") capsules 5 mg, administered orally once daily.
Experimental: Xanamem® 10 mg
Oral Xanamem® capsules 10 mg, to be administered once daily
Drug: Xanamem® 10 mg
Oral Xanamem® ("UE2343") capsules 10 mg, administered orally once daily.
Placebo Comparator: Placebo
Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
- Short-term efficacy: Assessment of changes of different doses of Xanamem® on cognition. [ Time Frame: Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up) ]Using a tailored Cogstate Neuropsychological Test Battery (NTB), changes from baseline, as well as composite scores based on a combination of these variables at each treatment visit [Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up)] will be analyzed.
- Assessment of safety and tolerability of different Xanamem® doses by the occurrence of Treatment-Emergent Adverse Events (TEAEs). [ Time Frame: 10 Weeks [Baseline to Week 10 Follow-Up (4 Weeks Post Last Dose of Study Drug)] ]The number, type, and severity of Treatment-Emergent Adverse Events (TEAEs) that are reported from Baseline to Follow-up Visit will be collected and evaluated.
- Short-term efficacy of different doses of Xanamem® on cognition [ Time Frame: Screening, Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up) ]Using the International Daily Digit Symbol Substitution Test-Symbols, to analyze changes from Screening to, Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Male or female aged 50 to 80
- Body mass index 17.5 to < 35 kg/m2, inclusive at the time of screening
- Mini-Mental State Score of ≥ 25 points at screening
- Must provide written informed consent
- Abnormalities in vital signs at screening or baseline
- Clinically significant abnormal hematology or biochemistry values, as determined by the investigator at screening and/or baseline.
- Previous clinically significant systemic illness or infection within the past 4 weeks prior to screening or baseline, as determined by the investigator
- Clinically significant ECG abnormalities
- Use of tobacco- or nicotine-containing products in the past month or unwillingness to abstain during study participation
- Participation in another clinical study of a drug or device
- Known allergy to the study drug (Xanamem®) or any of the excipients
- Subjects who are likely to be unable to comply with the study schedule and/ or subjects with an inability to communicate well with the investigator
- Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies at screening
- Subjects with a history of drug abuse or addiction in the past 5 years.
- Evidence of alcohol abuse (defined as greater than 21 standard units per week for males and greater than 14 standard units per week for females)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04983368
|Australia, Australian Capital Territory|
|Paratus Clinical Research Canberra|
|Bruce, Australian Capital Territory, Australia, 2617|
|Australia, New South Wales|
|Paratus Clinical Research Western Sydney|
|Blacktown, New South Wales, Australia, 2148|
|Paratus Clinical Research Central Coast|
|Kanwal, New South Wales, Australia, 2259|
|Paratus Clinical Research Brisbane|
|Albion, Queensland, Australia, 4010|
|USC Clinical Trials|
|Sippy Downs, Queensland, Australia, 4556|
|Study Director:||Miriam Roesner||Actinogen Medical Limited|
|Responsible Party:||Actinogen Medical|
|Other Study ID Numbers:||
|First Posted:||July 30, 2021 Key Record Dates|
|Last Update Posted:||April 8, 2022|
|Last Verified:||April 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Central Nervous System Diseases
Nervous System Diseases